Ing. Michal Pohludka, PhD. MBA, LL.M.
He graduated in biochemistry and biotechnology at the University of Chemical Technology in Prague, followed by postgraduate studies at the Institute of Hereditary Metabolic Disorders, 1st Faculty of Medicine, Charles University in Prague. Since 2004 he has been working on 1st Fculty of Medicine of Charles University in Prague where he was involved in research of nuclear hormonal receptors with the objective of discovering the gene expresison regulators in cancer cells. In 2008, he began working in the commercial sector. For over ten years (2008 – 2019) he worked in Bio-Rad Laboratories, the global US company which provides compehensive solutions in the field of clinical diagnostics and for scientific centers.
From the publishing point of view, his activity is very diverse. From his career at the 1st Faculty of Medicine in Charles University in Prague, he has several publications from genomics and proteomics. In 2010, in cooperation with the University Hospital Brno a.s. and 1st Faculty fo Medicine of Charles University in Prague, he published methodology publication on a new clinical-diagnostic approach to the detection of asialotransferrin in cerebrospinal fluid. Since 2018, in cooperation with EF VŠB-TU Ostrava, he has published a number of publications in the field of business management and company operations.
He cooperates with MEDIREX GROUP ACADEMY on the following projects:
Creating a system of early and rapid detection, identification and diagnosis of new infectious diseases with pandemic potential – pilot study COVID-19
Research into progressive diagnostic methods for COVID-19 and biomarkers enabling early detection of individuals at increased risk of severe course of the disease